X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaqnrxp-chairman-dr-jonathan-javitt-to-present-at-the-ketamine-2024-conference-in-oxford-uk-302097763.html
https://www.pharmaceutical-technology.com/data-insights/ketamine-er-douglas-pharmaceuticals-major-depressive-disorder-likelihood-of-approval/?cf-view
https://www.globenewswire.com/news-release/2023/06/27/2695149/0/en/PharmaTher-Initiates-Filing-of-Abbreviated-New-Drug-Application-for-KETARX-racemic-ketamine-to-the-FDA.html
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-may-24-2023-89772.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215808
https://www.globenewswire.com/news-release/2022/12/15/2574490/0/en/PharmaTher-Announces-FDA-Orphan-Drug-Designation-Granted-to-Ketamine-for-Prevention-of-Ischemia-Reperfusion-Injury-from-Organ-Transplantation.html
https://www.globenewswire.com/news-release/2022/11/14/2554911/0/en/PharmaTher-Announces-Poster-Presentation-of-Positive-Efficacy-and-Safety-Data-from-Phase-1-2-Clinical-Study-of-Ketamine-in-the-Treatment-of-Levodopa-Induced-Dyskinesia-in-Parkinson.html
https://health.economictimes.indiatimes.com/news/pharma/stigma-in-drug-research-holding-back-new-therapies/94760467
https://neurosciencenews.com/ketmaine-administration-gender-21329/
https://www.prnewswire.com/news-releases/ketamine-ushering-in-new-era-in-the-pharmacology-therapies-for-neurological-disorders-301594291.html
https://www.globenewswire.com/news-release/2022/07/13/2478839/0/en/PharmaTher-Announces-Notice-of-Allowance-for-U-S-Patent-Covering-Ketamine-for-the-Potential-Treatment-of-Parkinson-s-Disease-and-Motor-Disorders.html
https://www.globenewswire.com/news-release/2022/06/29/2471120/0/en/PharmaTher-Announces-Positive-Results-from-Study-For-Ketamine-Microneedle-Patch.html
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-june-8-2022-1654674832.pdf
https://www.globenewswire.com/news-release/2022/06/08/2458726/0/en/First-patient-dosed-in-second-Phase-2-add-on-Ketamine-Trial-in-Treatment-Resistant-Depression-TRD.html
https://www.fiercepharma.com/pharma/pharmather-fleshes-out-ketamine-delivery-portfolio-deal-body-injector
https://www.fiercepharma.com/pharma/oral-prolonged-release-ketamine-advances-after-covid-disrupted-trial
https://www.prnewswire.com/news-releases/braxia-scientific-provides-update-on-large-proprietary-dataset-expected-to-support-pharmaceutical-and-industry-clinical-trials-for-ketamine-and-psilocybin-drug-development-301471326.html
https://www.globenewswire.com/news-release/2022/01/12/2365560/0/en/PharmaTher-Announces-FDA-Approval-of-Investigational-New-Drug-IND-Application-for-Ketamine-to-Treat-ALS.html
https://www.globenewswire.com/news-release/2022/01/12/2365542/0/en/atai-Life-Sciences-announces-FDA-Investigational-New-Drug-IND-Clearance-for-PCN-101-R-ketamine-Program.html
https://www.prnewswire.com/news-releases/accp-policy-statements-offlabel-use-of-ketamine-a-challenging-drug-treatment-delivery-model-with-an-inherently-unfavorable-riskbenefit-profile--pharmacological-arguments-against-the-use-of-ketamine-in-non-medical-settings-301454747.html
https://trialsitenews.com/university-of-exeter-data-analysis-shows-ketamine-swiftly-treats-the-symptoms-of-depression-and-suicidal-thoughts/
https://www.globenewswire.com/news-release/2021/12/20/2355119/0/en/PharmaTher-Enters-Into-Process-Development-Agreement-With-LTS-LOHMANN-for-Ketamine-Microneedle-Patch.html
https://www.prnewswire.com/news-releases/seelos-therapeutics-announces-acquisition-of-an-exclusive-license-of-ix-biopharmas-proprietary-wafer-based-delivery-platform-for-sublingual-ketamine-301431260.html
https://www.globenewswire.com/news-release/2021/11/24/2340517/0/en/PharmaTher-Applies-for-FDA-Orphan-Drug-Designation-for-Ketamine-to-Treat-Rare-Neurological-Disorder-Status-Epilepticus.html
https://www.prnewswire.com/news-releases/bexson-biomedical-announces-expansion-to-treat-major-depression-with-wearable-ketamine-formulation-301428482.html
https://www.prnewswire.com/news-releases/braxia-scientific-announces-voting-results-from-the-annual-general-meeting-of-shareholders-301412307.html
https://www.prnewswire.com/news-releases/ketamines-potential-as-a-treatment-for-depression-has-drawn-major-industry-attention-301409434.html
https://www.globenewswire.com/news-release/2021/10/19/2316353/0/en/PharmaTher-Engages-Alcami-for-Clinical-and-Commercial-Manufacturing-of-Novel-Ketamine-Products.html
https://endpts.com/fda-warns-minnesota-doc-for-running-two-ketamine-trials-without-inds-and-with-children-and-a-pregnant-woman/
https://www.globenewswire.com/news-release/2021/10/14/2313950/0/en/Ketamine-One-Launching-Two-Inaugural-Research-Studies.html
https://www.prnewswire.com/news-releases/braxia-scientific-reports-encouraging-results-of-ketamine-study-showing-significant-reduction-in-depressive-symptoms-and-suicidality-with-ketamine-as-a-solo-treatment-301388447.html
https://www.globenewswire.com/news-release/2021/09/14/2296596/0/en/Perception-Neuroscience-initiates-Phase-2a-study-of-PCN-101-R-ketamine-for-treatment-resistant-depression.html
https://www.pharmacompass.com/pdf/news/aikido-pharma-files-patent-application-for-the-use-of-ketamine-1626764742.pdf
https://www.globenewswire.com/news-release/2021/06/10/2245151/0/en/PharmaTher-Provides-Research-and-Development-Update-and-Milestones-for-2021.html
https://www.globenewswire.com/news-release/2021/04/27/2217503/0/en/PharmaTher-Expands-Patent-Portfolio-with-Filing-of-U-S-Patent-Application-for-Ketamine-and-Repurposing-of-Psychedelics-with-panaceAI.html
https://www.prnewswire.com/news-releases/seelos-therapeutics-announces-completion-of-open-label-patient-enrollment-of-proof-of-concept-study-of-sls-002-intranasal-racemic-ketamine-for-acute-suicidal-ideation-and-behavior-in-patients-with-major-depressive-disorder-301241165.html
https://www.biospace.com/article/releases/core-one-labs-finalizes-deal-to-acquire-ketamine-infusions-centers-of-texas-entering-the-us-market-for-psychedelic-treatments/?s=79
https://www.prnewswire.com/news-releases/seelos-therapeutics-announces-dosing-of-the-first-patients-in-a-study-of-sls-002-intranasal-racemic-ketamine-for-acute-suicidal-ideation-and-behavior-in-patients-with-major-depressive-disorder-301208880.html
https://www.newswise.com/articles/repeated-ketamine-infusions-reduce-symptom-severity-in-individuals-with-chronic-post-traumatic-stress-disorder
https://endpts.com/after-psilocybin-and-ketamine-a-new-biotech-comes-along-developing-a-drug-scott-gottlieb-tried-to-ban/
https://www.globenewswire.com/news-release/2020/06/23/2051864/0/en/Seelos-Therapeutics-Announces-Final-Data-from-Phase-I-PK-PD-Study-of-Intranasal-Racemic-Ketamine-SLS-002-and-Clinical-Development-Plans.html
https://www.globenewswire.com/news-release/2020/06/12/2047643/0/en/Champignon-Provides-Corporate-Update-Announces-Name-Change-Rebranding-and-Planned-Spin-Out.html
https://www.globenewswire.com/news-release/2020/06/08/2044676/0/en/Champignon-Identifies-Synthetic-Ketamine-and-Psilocybin-Psilicin-Metabolite-Targets-Selects-Dalriada-to-Advance-NCE-IP-Portfolio.html
https://medicalxpress.com/news/2020-06-ketamine-combats-depression.html
Market Place
Share 
